Newsbenzinga
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market
· Published
Article summary
Cartesian Therapeutics gains after licensing an in vivo CAR-T platform from WestGene, with a myasthenia gravis trial planned for 2026.
An excerpt from the original article.
Comments —
Loading comments…